Marianne Just

Teutoburger Str. 60 33604
Bielefeld, NW 33604, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.

Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 18, 2026

Surgical axillary intervention after neoadjuvant systemic therapy (NST) for early-stage breast cancer - Clinical significance of micrometastases: Data from five neoadjuvant studies.

Surgical axillary intervention after neoadjuvant systemic therapy (NST) for early-stage breast cancer - Clinical significance of micrometastases: Data from five neoadjuvant studies.

Journal: Breast (Edinburgh, Scotland)

Published: January 05, 2026

First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA study.

First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA study.

Journal: ESMO open

Published: December 10, 2025

Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N = 7914).

Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N = 7914).

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: July 10, 2025

Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX).

Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX).

Journal: ESMO open

Published: June 18, 2025

Prediction of survival after de-escalated neoadjuvant therapy in HER2-positive early breast cancer: a pooled analysis of three WSG trials.

Prediction of survival after de-escalated neoadjuvant therapy in HER2-positive early breast cancer: a pooled analysis of three WSG trials.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: April 30, 2025

Endocrine response assessment in HR-positive HER2-negative early breast cancer: concordance of local versus central Ki67 measurements in the WSG ADAPTcycle trial (n = 5292).

Endocrine response assessment in HR-positive HER2-negative early breast cancer: concordance of local versus central Ki67 measurements in the WSG ADAPTcycle trial (n = 5292).

Journal: ESMO open

Published: April 07, 2025

Long-term outcome data for patients with hormone receptor-positive early breast cancer participating in the WSG PlanB trial after preselection by gene expression analysis: 10-year survival results from the WSG PlanB registry.

Long-term outcome data for patients with hormone receptor-positive early breast cancer participating in the WSG PlanB trial after preselection by gene expression analysis: 10-year survival results from the WSG PlanB registry.

Journal: ESMO open

Published: March 28, 2025

Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma.

Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma.

Journal: Leukemia

Published: August 02, 2023

Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate - The ICE randomized clinical trial.

Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate - The ICE randomized clinical trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 22, 2023

RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial.

RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 14, 2023

Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial.

Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial.

Journal: JAMA oncology

Published: May 11, 2023

Showing 1-12 of 29

Last Updated: 09/26/2026